Phosphonate Compounds
AssigneeThe Regents of the University of California
InventorsKarl Y. Hostetler, James R. Beadle, Ganesh D. Kini
Life of this patent
Estimating the term…
Abstract
The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.
Claims23
An antiviral nucleoside compound having the structure of Formula I:
- wherein:
- R1 is —O—(CH2)t—CH3, wherein t is 11 to 19;
- a is 2 to 4;
- B is hydrogen, —CH3, or —CH2OH,
- Z is
- and the symbol * indicates that -*CH2— in Formula I is attached to Z via N* in Formula A or B;
- a pharmaceutically acceptable salt or a stereochemically isomeric form thereof.
(canceled)
A pharmaceutical composition comprising an effective amount of an antiviral nucleoside compound of Formula I
- wherein:
- R1 is —O—(CH2)t—CH3, wherein t is 11 to 19;
- a is 2 to 4;
- B is hydrogen, —CH3, or —CH2OH,
- Z is
- and the symbol * indicates that -*CH2— in Formula I is attached to Z via N* in Formula A or B,
- or a pharmaceutically acceptable salt thereof;
- in combination with a pharmaceutically acceptable carrier.
(canceled)
A method for the treatment of a viral disease comprising administering an effective amount of an antiviral nucleoside compound of Formula I
- wherein:
- R1 is —O—(CH2)t—CH3, wherein t is 11 to 19;
- a is 2 to 4;
- B is hydrogen, —CH3, or —CH2OH,
- Z is
- and the symbol * indicates that -*CH2— in Formula I is attached to Z via N* in Formula A or B,
- or a pharmaceutically acceptable salt thereof;
- optionally in a pharmaceutically acceptable carrier.
(canceled)
Dependencies are inferred from the claim text.